Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...olorectal carcinoma patients being considered...
...V600 (BRAF c. 1799 (p.V600) mutational analy...
...mutational analysis should be performed in...
...d order mismatch repair status testing in patients...
...sufficient evidence to recommend BR...
There is insufficient evidence to recommend PIK3CA...
...is insufficient evidence to recommend PTEN analy...
...or recurrent colorectal carcinoma tissues are...
...araffin embedded tissue is an acceptable sp...
...st use validated colorectal carcinoma molecular...
...rmance of molecular biomarker testi...
...st validate the performance of IHC...
...boratories must provide clinically appr...
...olecular and IHC biomarker testing in color...
...atories should establish policies to e...
...the patient’s medical team, including patholog...
...oratories that require send out of tests for tr...
...thologists must evaluate candidate spe...
...ries should use colorectal carcinoma molecular bio...
...cinoma molecular biomarker results shoul...
...carcinoma molecular biomarker testing reports...
...ust incorporate colorectal carcinoma mo...
...mes of RAS Mutations and Anti-EGFR Therapy...
...2. Concordance Rates Between Primary...